| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gwenaëlle Le Pen, Jean-Luc Morea. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 1. 2002-08-08. PMID:12062902. |
disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. |
2002-08-08 |
2023-08-12 |
rat |
| Igor Elman, David S Goldstein, Alan I Green, Graeme Eisenhofer, Carol J Folio, Courtney S Holmes, David Pickar, Alan Breie. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 2. 2002-08-07. PMID:12093603. |
effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. |
2002-08-07 |
2023-08-12 |
Not clear |
| Hassan S Dinakar, Robert N Sobel, James H Bopp, Anita Daniels, Sondra Maur. Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. Psychiatric services (Washington, D.C.). vol 53. issue 6. 2002-08-01. PMID:12045315. |
the authors studied the efficacy of olanzapine and risperidone among patients with treatment-refractory schizophrenia who had been hospitalized for more than five years and who were not suitable candidates for a clozapine trial. |
2002-08-01 |
2023-08-12 |
Not clear |
| Arja Tuunainen, Kristian Wahlbeck, Simon Gilbod. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophrenia research. vol 56. issue 1-2. 2002-07-31. PMID:12084413. |
the aim of this study was to evaluate the effectiveness of newer atypical antipsychotic drugs in comparison to clozapine for schizophrenia. |
2002-07-31 |
2023-08-12 |
Not clear |
| G W Eschweiler, M Bartels, G Längle, B Wild, I Gaertner, M Nickol. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? Pharmacopsychiatry. vol 35. issue 3. 2002-07-31. PMID:12107853. |
the plasma concentrations of the atypical antipsychotics clozapine and olanzapine correlated with parameters of hrv in 59 patients suffering from schizophrenia or schizoaffective disorder. |
2002-07-31 |
2023-08-12 |
Not clear |
| K Raaska, V Raitasuo, P J Neuvone. Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. European journal of clinical pharmacology. vol 57. issue 10. 2002-07-23. PMID:11829199. |
effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. |
2002-07-23 |
2023-08-12 |
Not clear |
| K Raaska, V Raitasuo, P J Neuvone. Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. European journal of clinical pharmacology. vol 57. issue 10. 2002-07-23. PMID:11829199. |
to study the effect of influenza vaccine on serum clozapine, n-desmethylclozapine and clozapine-n-oxide steady-state concentrations in patients with schizophrenia. |
2002-07-23 |
2023-08-12 |
Not clear |
| Dalu Mancama, Maria J Arranz, Robert W Kerwi. Genetic predictors of therapeutic response to clozapine: current status of research. CNS drugs. vol 16. issue 5. 2002-07-23. PMID:11994021. |
clozapine is one of the most clinically potent drugs currently available for treating the symptoms of schizophrenia. |
2002-07-23 |
2023-08-12 |
Not clear |
| Thomas A Pugsley, Yu Hsin Shih, Steven Z Whetzel, Kim Zoski, Don Van Leeuwen, Hyacinth Akunne, R Mackenzie, Thomas G Heffner, David Wustrow, Lawrence D Wis. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists. Progress in neuro-psychopharmacology & biological psychiatry. vol 26. issue 2. 2002-07-22. PMID:11817497. |
the da d4 receptor is of interest as a target for drugs to treat schizophrenia based upon its high affinity for the atypical antipsychotic clozapine and its localization to the limbic and cortical regions of the brain. |
2002-07-22 |
2023-08-12 |
mouse |
| Juan M Manzaneque, Paul F Brain, Jose F Navarr. Effect of low doses of clozapine on behaviour of isolated and group-housed male mice in the elevated plus-maze test. Progress in neuro-psychopharmacology & biological psychiatry. vol 26. issue 2. 2002-07-22. PMID:11817513. |
clozapine is effective over a low and narrow dose range in the treatment of the negative symptoms of schizophrenia. |
2002-07-22 |
2023-08-12 |
mouse |
| Glen L Stimmel, Mary A Gutierrez, Vivian Le. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clinical therapeutics. vol 24. issue 1. 2002-07-10. PMID:11833834. |
over the past decade, use of the atypical antipsychotic drugs clozapine, risperidone, olanzapine, and quetiapine has significantly changed the treatment of schizophrenia in the united states. |
2002-07-10 |
2023-08-12 |
Not clear |
| Long Chen, Charles R Yan. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. Journal of neurophysiology. vol 87. issue 5. 2002-06-28. PMID:11976371. |
the atypical antipsychotic drug clozapine effectively alleviates both negative and positive symptoms of schizophrenia via unclear cellular mechanisms. |
2002-06-28 |
2023-08-12 |
rat |
| Long Chen, Charles R Yan. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. Journal of neurophysiology. vol 87. issue 5. 2002-06-28. PMID:11976371. |
this sequence of early synaptic events induced by acute clozapine may comprise part of the activity that leads to later cognitive improvement in schizophrenia. |
2002-06-28 |
2023-08-12 |
rat |
| S Avissar, G Roitman, G Schreibe. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cellular and molecular neurobiology. vol 21. issue 6. 2002-06-25. PMID:12043849. |
differential effects of the antipsychotics haloperidol and clozapine on g protein measures in mononuclear leukocytes of patients with schizophrenia. |
2002-06-25 |
2023-08-12 |
Not clear |
| S Avissar, G Roitman, G Schreibe. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cellular and molecular neurobiology. vol 21. issue 6. 2002-06-25. PMID:12043849. |
the present study aims at investigating the effect of antipsychotic medications on dopamine-induced gs protein hyperfunction in schizophrenia comparing the classical antipsychotic haloperidol and the newer antipsychotic clozapine, which is devoid of extrapyramidal side effects, on g protein measures. |
2002-06-25 |
2023-08-12 |
Not clear |
| Robert M Bilder, Robert S Goldman, Jan Volavka, Pal Czobor, Matthew Hoptman, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph McEvoy, Michal Kunz, Miranda Chakos, Thomas B Cooper, Terri L Horowitz, Jeffrey A Lieberma. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. The American journal of psychiatry. vol 159. issue 6. 2002-06-21. PMID:12042192. |
neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. |
2002-06-21 |
2023-08-12 |
Not clear |
| Daniel S Umbricht, William C Wirshing, Donna A Wirshing, Marjorie McMeniman, Nina R Schooler, Stephen R Marder, John M Kan. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of clinical psychiatry. vol 63. issue 5. 2002-06-06. PMID:12019667. |
clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. |
2002-06-06 |
2023-08-12 |
Not clear |
| Michael Maes, Luisella Bocchio Chiavetto, Stefano Bignotti, Giani-Jean Battisa Tura, Rosaria Pioli, Francesco Boin, Gunter Kenis, Eugene Bosmans, Raf de Jongh, Carlo A Altamur. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophrenia research. vol 54. issue 3. 2002-06-04. PMID:11950553. |
it is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum lif-r concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment. |
2002-06-04 |
2023-08-12 |
human |
| Mary C Borovicka, Matthew A Fuller, P Eric Konicki, John C White, Vickie M Steele, George E Jaski. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. The Journal of clinical psychiatry. vol 63. issue 4. 2002-05-31. PMID:12000209. |
phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. |
2002-05-31 |
2023-08-12 |
Not clear |
| V Raitasu. [Clozapine in the treatment of schizophrenia]. Duodecim; laaketieteellinen aikakauskirja. vol 116. issue 11. 2002-05-24. PMID:11989005. |
[clozapine in the treatment of schizophrenia]. |
2002-05-24 |
2023-08-12 |
Not clear |